We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Determining if Tumor Gene Testing Can Select Efficacious Precision Cancer Treatments

News   Oct 14, 2020 | Original story from ECOG-ACRIN

 
Determining if Tumor Gene Testing Can Select Efficacious Precision Cancer Treatments

NCI-MATCH is a precision medicine cancer trial that seeks to determine whether matching certain drugs or drug combinations in adults whose tumors have specific gene abnormalities will effectively treat their cancer, regardless of their cancer type. Such discoveries could be eligible to move on to larger, more definitive trials. The trial is led by the ECOG-ACRIN Cancer Research Group. Credit: ECOG-ACRIN Cancer Research Group

 
 
Advertisement
 

RELATED ARTICLES

Anemone Produce Toxins That Have Pharmacological Potential

News

Researchers based in Brazil and the United States have completed the first-ever mapping exercise to profile the toxins produced by tube-dwelling anemones, or cerianthids, a family of marine animals. The analysis revealed that the toxins that can act on the nervous system, cardiovascular system, and cell walls, among other functions, paving the way to the discovery of novel medications.

READ MORE

Scientists Analyze Over Half a Million Chemical-Gene Interactions

News

A University of Massachusetts Amherst environmental health scientist has used an unprecedented objective approach to identify which molecular mechanisms in mammals are the most sensitive to chemical exposures.

READ MORE

Why Are Some People Infected With COVID-19 Asymptomatic?

News

A team of researchers from Aarhus University and Aarhus University Hospital in Denmark set out to investigate how important immune cells react to the SARS-CoV-2 virus.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE